Generic Drug Assessment Times Show Improvement In GDUFA Performance Report
Executive Summary
Averages likely will increase as more of the cohort is approved, however.
You may also be interested in...
US Complex Generics Need New Communication Channels
US FDA and complex generic sponsors need a way to talk about reference product and other changes once the pre-submission meetings pathway is exhausted.
Complex Generics May Need New Communications Options In GDUFA III
US FDA and complex generic sponsors need a way to talk about reference product and other changes once the pre-submission meetings pathway is exhausted.
ANDA Reviews Sometimes Miss GDUFA Goal Dates To Get Quicker Approval, But How Often?
Preliminary performance data suggests only a handful of applications receiving US FDA action by the end of FY 2018 actually missed their review goals.